Volume 381, Issue 9875, Pages 1391-1403 (April 2013) Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial    The Lancet  Volume 381, Issue 9875, Pages 1391-1403 (April 2013) DOI: 10.1016/S0140-6736(12)62198-9 Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile Study ended on March 16, 2012. ART=antiretroviral therapy. *Predominant reason for ineligibility given according to frequency. † First randomisation included, second excluded. ‡Communication error at enrolment. §Both on intensive phase of tuberculosis treatment. The Lancet 2013 381, 1391-1403DOI: (10.1016/S0140-6736(12)62198-9) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 2 Substitution in first-line ART (any reason) and switch to second-line ART (A) By monitoring strategy. (B) By ART strategy. Lines show cumulative incidence of switch to second-line treatment before death on first-line, and of substitution in first-line before death on first-line estimated treating death on first-line as a competing risk. ART=antiretroviral therapy. CHR=cause-specific hazard ratio. CDM=clinically driven monitoring. LCM=laboratory and clinical monitoring. The Lancet 2013 381, 1391-1403DOI: (10.1016/S0140-6736(12)62198-9) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 3 New WHO 4 stage event or death (A), CD4 (B), viral load (C), and adverse events (D), by monitoring strategy CDM=clinically driven monitoring. LCM=laboratory and clinical monitoring. ART=antiretroviral therapy. AE=adverse event. SAE=serious adverse event. *CD4 cell count in children aged 5 years or older at ART initiation. † Upper lines show suppression less than 400 copies per mL and lower lines suppression less than 80 copies per mL (2:1 dilution used for most samples because of low stored volumes). The Lancet 2013 381, 1391-1403DOI: (10.1016/S0140-6736(12)62198-9) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 4 New WHO 4 stage event or death (A), CD4 (B), viral load (C), and adverse events (D), by ART strategy ART=antiretroviral therapy. AE=adverse event. SAE=serious adverse event. *CD4 cell count in children aged 5 years or older at ART initiation. † Upper lines show suppression less than 400 copies per mL and lower lines suppression less than 80 copies per mL (2:1 dilution used for most samples because of low stored volumes). The Lancet 2013 381, 1391-1403DOI: (10.1016/S0140-6736(12)62198-9) Copyright © 2013 Elsevier Ltd Terms and Conditions